Ketoacidosis with euglycemia in a patient with type 2 diabetes mellitus taking dapagliflozin: A case report. Yeo, S. M., Park, H., Paek, J. H., Park, W. Y., Han, S., Park, S. B., & Jin, K. Medicine, 98(3):e14150, January, 2019.
Ketoacidosis with euglycemia in a patient with type 2 diabetes mellitus taking dapagliflozin: A case report [link]Paper  doi  abstract   bibtex   
Rationale: Dapagliflozin (a sodium-glucose cotransporter-2 [SGLT2] inhibitor) represents the most recently approved class of oral medications for the treatment of type 2 diabetes. Dapagliflozin lowers plasma glucose concentration by inhibiting the renal reuptake of glucose in the proximal renal tubules. In 2015, the US Food and Drug Administration released a warning concerning a potential increased risk of ketoacidosis in patients taking this medication.
@article{yeo_ketoacidosis_2019,
	title = {Ketoacidosis with euglycemia in a patient with type 2 diabetes mellitus taking dapagliflozin: {A} case report},
	volume = {98},
	issn = {0025-7974},
	shorttitle = {Ketoacidosis with euglycemia in a patient with type 2 diabetes mellitus taking dapagliflozin},
	url = {http://Insights.ovid.com/crossref?an=00005792-201901180-00067},
	doi = {10.1097/MD.0000000000014150},
	abstract = {Rationale: Dapagliflozin (a sodium-glucose cotransporter-2 [SGLT2] inhibitor) represents the most recently approved class of oral medications for the treatment of type 2 diabetes. Dapagliflozin lowers plasma glucose concentration by inhibiting the renal reuptake of glucose in the proximal renal tubules. In 2015, the US Food and Drug Administration released a warning concerning a potential increased risk of ketoacidosis in patients taking this medication.},
	language = {en},
	number = {3},
	urldate = {2019-06-02},
	journal = {Medicine},
	author = {Yeo, Sang Mok and Park, Hayeon and Paek, Jin Hyuk and Park, Woo Yeong and Han, Seungyeup and Park, Sung Bae and Jin, Kyubok},
	month = jan,
	year = {2019},
	pages = {e14150}
}

Downloads: 0